TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company
Transcenta, biologics, antibody
TST004 is a humanized mAb targeting mannan-binding lectin serine protease 2 (MASP2) and designed to prevent the inflammation and tissue damage mediated by lectin pathway complement activation. TST004 is currently at IND-enabling stage with GLP toxicology studies and CMC studies ongoing.
Nature Reviews Nephrology (2017) 13:311–318
